MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wnendt, S.
Right arrow Articles by Englberger, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wnendt, S.
Right arrow Articles by Englberger, W.

Vol. 56, Issue 2, 334-338, August 1999

Agonistic Effect of Buprenorphine in a Nociceptin/OFQ Receptor-Triggered Reporter Gene Assay

Stephan Wnendt, Thomas Krüger, Elke Janocha, Dieter Hildebrandt, and Werner Englberger

Department of Molecular Pharmacology, Grünenthal GmbH, Aachen, Germany

The role of the opioid-like receptor 1 (ORL1) and its endogenous ligand, nociceptin/orphanin FQ (N/OFQ), in nociception, anxiety, and learning remains to be defined. To allow the rapid identification of agonists and antagonists, a reporter gene assay has been established in which the ORL1 receptor is functionally linked to the cyclic AMP-dependent expression of luciferase. N/OFQ and N/OFQ1-13NH2 inhibited the forskolin-induced luciferase gene expression with IC50 values of 0.81 ± 0.5 and 0.87 ± 0.16 nM, respectively. Buprenorphine was identified as a full agonist at the ORL1 receptor with an IC50 value of 8.4 ± 2.8 nM. Fentanyl and 7-benzylidenenaltrexone displayed a weak agonistic activity. The ORL1 antagonist [Phe1Psi (CH2-NH)Gly2]N/OFQ(1-13)NH2 clearly behaved as an agonist in this assay with an IC50 value of 85 ± 47 nM. Thus, there is still a need for antagonistic tool compounds that might help to elucidate the neurophysiological role of N/OFQ.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. D. Recker and G. A. Higgins
The Opioid Receptor Like-1 Receptor Agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) Produces a Discriminative Stimulus in Rats Distinct from That of a {micro}, {kappa}, and {delta} Opioid Receptor Agonist Cue
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 652 - 658.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
S. Takeda, T. Okada, M. Okamura, T. Haga, J. Isoyama-Tanaka, H. Kuwahara, and N. Minamino
The Receptor-G{alpha} Fusion Protein as a Tool for Ligand Screening: a Model Study Using a Nociceptin Receptor-G{alpha}i2 Fusion Protein
J. Biochem., May 1, 2004; 135(5): 597 - 604.
[Abstract] [Full Text] [PDF]

Home page
 RNAHome page
D. FAULHAMMER, B. ESCHGFALLER, S. STARK, P. BURGSTALLER, W. ENGLBERGER, J. ERFURTH, F. KLEINJUNG, J. RUPP, S. D. VULCU, W. SCHRODER, et al.
Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ
RNA, March 1, 2004; 10(3): 516 - 527.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K. Lutfy, S. Eitan, C. D. Bryant, Y. C. Yang, N. Saliminejad, W. Walwyn, B. L. Kieffer, H. Takeshima, F. I. Carroll, N. T. Maidment, et al.
Buprenorphine-Induced Antinociception Is Mediated by {micro}-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors
J. Neurosci., November 12, 2003; 23(32): 10331 - 10337.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Huang, G. B. Kehner, A. Cowan, and L.-Y. Liu-Chen
Comparison of Pharmacological Activities of Buprenorphine and Norbuprenorphine: Norbuprenorphine Is a Potent Opioid Agonist
J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 688 - 695.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics